NASDAQ:ATTO Attovia Therapeutics Q3 2026 Earnings Results & Report $14.96 -1.00 (-6.24%) As of 09:36 AM Eastern This is a fair market value price provided by Massive. Learn more. Attovia Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.76 versus the -$0.74 consensus estimate. Revenue decreased 100.0% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeAfter Market ClosesConference Call7:00 AM ET Attovia Therapeutics EPS ResultsActual EPS-$0.76Consensus EPS -$0.74Beat/MissMissed by -$0.02One Year Ago EPS-$3.44Attovia Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue Growth-100.00%Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Attovia Therapeutics Q3 2026 Earnings FAQ Did Attovia Therapeutics beat earnings estimates for Q3 2026? Attovia Therapeutics (NASDAQ:ATTO) reported earnings of -$0.76 per share for Q3 2026, missing the consensus estimate of -$0.74. The report was announced on Monday, November 9, 2026. Attovia Therapeutics Earnings HeadlinesAttovia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 3:54 AM | marketscreener.comMAttovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis TranscriptNovember 9 at 6:00 PM | seekingalpha.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 10 at 1:00 AM | Behind the Markets (Ad)Attovia Reports Positive Phase 1b Results for ATTO-1310November 9 at 5:31 PM | tipranks.comAttovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateNovember 9 at 4:05 PM | globenewswire.comAttovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic DermatitisNovember 5, 2026 | globenewswire.comSee More Attovia Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Attovia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Attovia Therapeutics and other key companies, straight to your email. Email Address About Attovia TherapeuticsAttovia Therapeutics (NASDAQ:ATTO) is a clinical-stage biotechnology company developing medicines for inflammatory and immune-mediated diseases. Its research focuses on antibody-based therapies intended to address biological pathways involved in these conditions. The company’s programs are in development, and its work centers on discovering and advancing potential treatments rather than marketing established products. Attovia Therapeutics is listed on the Nasdaq under the symbol ATTO. Publicly available information about the company’s history, leadership and geographic operations is limited.View Attovia Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength RemainsThe Ugly Truth Behind SoundHound’s Q3 Results Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
